2026 ICD-10-CM Diagnosis Code T47.1X5AAdverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
T47.1X5A is a billable ICD-10-CM diagnosis code for adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 917 through 918. The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Adverse effects of drugs and medicaments, initial encounter.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T47.1X5A.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Adverse reaction to alexitol sodium
- Adverse reaction to aluminum and/or aluminum compound
- Adverse reaction to calcium carbonate and/or etidronic acid
- Adverse reaction to hydrotalcite
- Adverse reaction to magaldrate
- Adverse reaction to magnesium carbonate
- Adverse reaction to oxytocic agents
- Adverse reaction to sodium bicarbonate
- Aluminum hydroxide adverse reaction
- Antacid adverse reaction
- Antacid bezoar
- Carbenoxolone adverse reaction
- Dimethicone adverse reaction
- Lansoprazole adverse reaction
- Magnesium trisilicate adverse reaction
- Medication bezoar
- Misoprostol adverse reaction
- Omeprazole adverse reaction
- Pirenzepine adverse reaction
- Proton pump inhibitor adverse reaction
- Sucralfate adverse reaction
- Terpenes adverse reaction
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily affecting the gastrointestinal system (T47). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Burimamide
an antagonist of histamine that appears to block both h2 and h3 histamine receptors. it has been used in the treatment of ulcers.Carbenoxolone
an agent derived from licorice root. it is used for the treatment of digestive tract ulcers, especially in the stomach. antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.Enprostil
a synthetic pge2 analog that has an inhibitory effect on gastric acid secretion, a mucoprotective effect, and a postprandial lowering effect on gastrin. it has been shown to be efficient and safe in the treatment of gastroduodenal ulcers.Metiamide
a histamine h2 receptor antagonist that is used as an anti-ulcer agent.Misoprostol
a synthetic analog of natural prostaglandin e1. it produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. it is an effective anti-ulcer agent and also has oxytocic properties.Omeprazole
a 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of stomach ulcers and zollinger-ellison syndrome. the drug inhibits an h(+)-k(+)-exchanging atpase which is found in gastric parietal cells.Pirenzepine
an antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. it promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. it also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. it is generally well tolerated by patients.Proglumide
a drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. it is used clinically in the drug therapy of gastrointestinal ulcers.Simethicone
a poly(dimethylsiloxane) which is a polymer of 200-350 units of dimethylsiloxane, along with added silica gel. it is used as an antiflatulent, surfactant, and ointment base.Sucralfate
a basic aluminum complex of sulfated sucrose.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T47.1X5A to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T47.1X5AOverview
Is T47.1X5A a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character A in T47.1X5A mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for adverse effect of other antacids and anti-gastric-secretion drugs, such as an emergency visit or first evaluation.
What MS-DRG does T47.1X5A group to?
On inpatient claims, adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter maps to MS-DRG 917, 918, with relative weights from 0.8571 to 1.5684 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T47.1X5A be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
What is the ICD-9 equivalent of T47.1X5A?
Under the General Equivalence Mappings, adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter converts to ICD-9-CM 995.29 (adv eff med/biol NEC/NOS) and E943.0 (adv eff antacids). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
